BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G. Is it possible to change phenotype progression in Crohn's disease in the era of immunomodulators? Predictive factors of phenotype progression. Am J Gastroenterol. 2014;109:1026-1036. [PMID: 24796767 DOI: 10.1038/ajg.2014.97] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Irwin J, Lord A, Ferguson E, Simms LA, Hanigan K, Montoya CA, Radford-Smith G. A Method Using Longitudinal Laboratory Data to Predict Future Intestinal Complication in Patients with Crohn's Disease. Dig Dis Sci 2022. [PMID: 36125595 DOI: 10.1007/s10620-022-07639-w] [Reference Citation Analysis]
2 Rezazadeh Ardabili A, Jeuring S, Mujagic Z, Oostenbrug L, Romberg-Camps M, Jonkers D, van Bodegraven A, Pierik M. Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35794735 DOI: 10.1111/apt.17128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 McKenna NP, Kelley SR, Bews KA, Behm KT, Mathis KL. Surgical Management of Enterovesical Fistula in Crohn's Disease in the Biologic Era. Inflamm Bowel Dis 2022:izac133. [PMID: 35751558 DOI: 10.1093/ibd/izac133] [Reference Citation Analysis]
4 Liu F, Tang J, Ye L, Tan J, Qiu Y, Hu F, He J, Chen B, He Y, Zeng Z, Mao R, Cao Q, Gao X, Chen M. Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study. Clin Transl Gastroenterol 2022;13:e00493. [PMID: 35758823 DOI: 10.14309/ctg.0000000000000493] [Reference Citation Analysis]
5 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
6 Gupta A, Pratap Mouli V, Mohta S, Kante B, Kalaivani M, Madhu D, Sahu P, Kumar S, Sharma R, Sahni P, Das P, Gupta SD, Makharia G, Kedia S, Ahuja V. Antitubercular Therapy Given to Differentiate Crohn's Disease From Intestinal Tuberculosis Predisposes to Stricture Formation. J Crohns Colitis 2020;14:1611-8. [PMID: 32369567 DOI: 10.1093/ecco-jcc/jjaa091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
7 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lopez RN, Day AS. The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:1390-1. [PMID: 32767152 DOI: 10.1007/s10620-020-06512-y] [Reference Citation Analysis]
9 Ochi M, Niikura R, Otsubo T, Yamada A, Kawai T, Koike K. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study. Int J Colorectal Dis 2021;36:2227-35. [PMID: 34386841 DOI: 10.1007/s00384-021-04007-4] [Reference Citation Analysis]
10 Calafat M, Mañosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert JP, Calvet X, García-López S, Monfort D, Pérez Calle JL, Riestra S, Gomollón F, Garcia-Planella E, Bermejo F, Hernández V, Martín-Arranz MD, Gutiérrez A, Torres P, Cañete F, Domènech E; ENEIDA registry of GETECCU . Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. J Crohns Colitis 2020;14:1290-8. [PMID: 32201893 DOI: 10.1093/ecco-jcc/jjaa055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Meima-van Praag EM, Buskens CJ, Hompes R, Bemelman WA. Surgical management of Crohn's disease: a state of the art review. Int J Colorectal Dis 2021;36:1133-45. [PMID: 33528750 DOI: 10.1007/s00384-021-03857-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Calafat M, Mañosa M, Cañete F, Domènech E. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs Aging 2021;38:193-203. [PMID: 33438138 DOI: 10.1007/s40266-020-00832-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rodríguez-Lago I, Hoyo JD, Pérez-Girbés A, Garrido-Marín A, Casanova MJ, Chaparro M, Fernández-Clotet A, Castro-Poceiro J, García MJ, Sánchez S, Ferreiro-Iglesias R, Bastón I, Piqueras M, Careda LEIB, Mena R, Suárez C, Cordón JP, López-García A, Márquez L, Arroyo M, Alfambra E, Sierra M, Cano N, Delgado-Guillena P, Morales-Alvarado V, Aparicio JC, Guerra I, Aulló C, Merino O, Arranz L, Hidalgo MA, Llaó J, Plaza R, Molina G, Torres P, Pérez-Galindo P, Romero MG, Herrera-deGuise C, Armesto E, Mesonero F, Frago-Larramona S, Benítez JM, Calvo M, Martín MDCL, Elorza A, Larena A, Peña E, Rodríguez-Grau MDC, Miguel-Criado J, Botella B, Olmos JA, López L, Aguirre U, Gisbert JP; Young GETECCU Group. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. United European Gastroenterol J 2020;8:1056-66. [PMID: 32723069 DOI: 10.1177/2050640620947579] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
14 Blackwell J, Saxena S, Jayasooriya N, Bottle A, Petersen I, Hotopf M, Alexakis C, Pollok RC. Prevalence and Duration of Gastrointestinal Symptoms Before Diagnosis of Inflammatory Bowel Disease and Predictors of Timely Specialist Review: A Population-Based Study. Journal of Crohn's and Colitis 2021;15:203-11. [DOI: 10.1093/ecco-jcc/jjaa146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
15 Frei R, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L. Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. J Crohns Colitis 2019;13:1292-301. [PMID: 30854548 DOI: 10.1093/ecco-jcc/jjz057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
16 Fiorino G, Bonifacio C, Allocca M, Danese S. Impact of therapies on bowel damage in Crohn's disease. United European Gastroenterol J 2020;8:410-7. [PMID: 32213030 DOI: 10.1177/2050640620908696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Yao JY, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. Development of a prognostic model for one-year surgery risk in Crohn’s disease patients: A retrospective study. World J Gastroenterol 2020; 26(5): 524-534 [PMID: 32089628 DOI: 10.3748/wjg.v26.i5.524] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Cernoch PS, Fournier N, Zeitz J, Scharl M, Morell B, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group. Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. Dig Dis Sci 2020;65:2654-63. [PMID: 31797187 DOI: 10.1007/s10620-019-05978-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Rodríguez-lago I, Gisbert JP. The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn’s Disease. Journal of Crohn's and Colitis 2020;14:557-66. [DOI: 10.1093/ecco-jcc/jjz158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
20 Landerholm K, Kalman D, Wallon C, Myrelid P. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease? CDT 2019;20:1384-98. [DOI: 10.2174/1389450120666190617163919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut 2019;68:623-32. [PMID: 29618498 DOI: 10.1136/gutjnl-2017-315521] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
22 Pimentel AM, Rocha R, Santana GO. Crohn’s disease of esophagus, stomach and duodenum. World J Gastrointest Pharmacol Ther 2019; 10(2): 35-49 [PMID: 30891327 DOI: 10.4292/wjgpt.v10.i2.35] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
23 Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, Salupere R, Pedersen N, Kjeldsen J, D'Incà R, Valpiani D, Schwartz D, Odes S, Olsen J, Nielsen KR, Vegh Z, Lakatos PL, Toca A, Turcan S, Katsanos KH, Christodoulou DK, Fumery M, Gower-Rousseau C, Zammit SC, Ellul P, Eriksson C, Halfvarson J, Magro FJ, Duricova D, Bortlik M, Fernandez A, Hernández V, Myers S, Sebastian S, Oksanen P, Collin P, Goldis A, Misra R, Arebi N, Kaimakliotis IP, Nikuina I, Belousova E, Brinar M, Cukovic-Cavka S, Langholz E, Munkholm P; Epi-IBD group. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2019;68:423-33. [PMID: 29363534 DOI: 10.1136/gutjnl-2017-315568] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 34.7] [Reference Citation Analysis]
24 Blackwell J, Saxena S, Pollok RC. Role of thiopurines as disease-modifying agents in Crohn's disease. Gut 2018;67:2229-30. [PMID: 29298871 DOI: 10.1136/gutjnl-2017-315840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Hoekman DR, Stibbe JA, Baert FJ, Caenepeel P, Vergauwe P, De Vos M, Hommes DW, Benninga MA, Vermeire SA, D'Haens GR; BIRD (Belgian Inflammatory Bowel Disease Research and Development) Group; North-Holland Gut Club. Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease. J Crohns Colitis. 2018;12:517-524. [PMID: 29401297 DOI: 10.1093/ecco-jcc/jjy014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
26 Arieira C, Cúrdia Gonçaves T, Dias de Castro F, João Moreira M, Cotter J. Clinical course in Crohn’s disease: factors associated with behaviour change and surgery. Scandinavian Journal of Gastroenterology 2018;53:1222-7. [DOI: 10.1080/00365521.2018.1503709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
27 Pernat Drobež C, Repnik K, Gorenjak M, Ferkolj I, Weersma RK, Potočnik U. DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease. Eur J Gastroenterol Hepatol 2018;30:447-55. [PMID: 29293112 DOI: 10.1097/MEG.0000000000001055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
28 Cross RK, Herfarth H. Is There a Role for Thiopurines in IBD? Am J Gastroenterol 2018;113:1121-4. [PMID: 29946181 DOI: 10.1038/s41395-018-0175-8] [Reference Citation Analysis]
29 Yung DE, Horesh N, Lightner AL, Ben-horin S, Eliakim R, Koulaouzidis A, Kopylov U. Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2327-38. [DOI: 10.1093/ibd/izy156] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
30 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
31 Pernat Drobež C, Ferkolj I, Potočnik U, Repnik K. Crohn's Disease Candidate Gene Alleles Predict Time to Progression from Inflammatory B1 to Stricturing B2, or Penetrating B3 Phenotype. Genet Test Mol Biomarkers 2018;22:143-51. [PMID: 29446656 DOI: 10.1089/gtmb.2017.0210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 252] [Cited by in F6Publishing: 207] [Article Influence: 63.0] [Reference Citation Analysis]
33 de Boer NKH, Peyrin-biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel J, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis 2018;12:610-20. [DOI: 10.1093/ecco-jcc/jjx181] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
34 Keane TJ, Dziki J, Sobieski E, Smoulder A, Castleton A, Turner N, White LJ, Badylak SF. Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis. J Crohns Colitis. 2017;11:360-368. [PMID: 27543807 DOI: 10.1093/ecco-jcc/jjw149] [Cited by in Crossref: 16] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
35 Fernandes SR, Rodrigues RV, Bernardo S, Cortez-pinto J, Rosa I, Pereira da Silva J, Gonçalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Venâncio J, Campos P, Dias Pereira A, Velosa J. Reply: . Inflammatory Bowel Diseases 2017;23:E45-6. [DOI: 10.1097/mib.0000000000001227] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
36 Kopylov U, Koulaouzidis A, Klang E, Carter D, Ben-Horin S, Eliakim R. Monitoring of small bowel Crohn's disease. Expert Rev Gastroenterol Hepatol 2017;11:1047-58. [PMID: 28737951 DOI: 10.1080/17474124.2017.1359541] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
37 Einarson TR, Bereza BG, Ying Lee X, Lelli F. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017;33:1433-49. [DOI: 10.1080/03007995.2017.1335001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Irwin J, Ferguson E, Simms LA, Hanigan K, Carbonnel F, Radford-Smith G. A rolling phenotype in Crohn's disease. PLoS One 2017;12:e0174954. [PMID: 28384331 DOI: 10.1371/journal.pone.0174954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
39 Amitai MM, Zarchin M, Lahat A, Yablecovitch D, Neuman S, Levhar N, Klang E, Avidan B, Ben-Horin S, Eliakim R, Kopylov U; Israeli IBD research Nucleus (IIRN). Structural bowel damage in quiescent Crohn's disease. Dig Liver Dis. 2017;49:490-494. [PMID: 28233685 DOI: 10.1016/j.dld.2017.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
40 Mantzaris GJ. Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era. Curr Treat Options Gastro 2017;15:84-104. [DOI: 10.1007/s11938-017-0128-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
41 Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:133-42. [DOI: 10.1097/mib.0000000000000988] [Cited by in Crossref: 117] [Cited by in F6Publishing: 56] [Article Influence: 23.4] [Reference Citation Analysis]
42 Rinawi F, Assa A, Hartman C, Mozer Glassberg Y, Nachmias Friedler V, Rosenbach Y, Silbermintz A, Zevit N, Shamir R. Evolution of disease phenotype in pediatric-onset Crohn’s disease after more than 10 years follow up—Cohort study. Digestive and Liver Disease 2016;48:1444-50. [DOI: 10.1016/j.dld.2016.08.118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
43 Barendregt J, de Jong M, Haans JJ, van Hoek B, Hardwick J, Veenendaal R, van der Meulen A, Srivastava N, Stuyt R, Maljaars J. Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn's disease. Int J Colorectal Dis 2017;32:459-67. [PMID: 27900523 DOI: 10.1007/s00384-016-2706-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
44 Bettenworth D, Rieder F. Reversibility of Stricturing Crohn's Disease-Fact or Fiction? Inflamm Bowel Dis 2016;22:241-7. [PMID: 26588089 DOI: 10.1097/MIB.0000000000000598] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
45 Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies: . Inflammatory Bowel Diseases 2016;22:1999-2015. [DOI: 10.1097/mib.0000000000000772] [Cited by in Crossref: 74] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
46 Szűcs D, Béres NJ, Rokonay R, Boros K, Borka K, Kiss Z, Arató A, Szabó AJ, Vannay &, Sziksz E, Bereczki C, Veres G. Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease. World J Gastroenterol 2016; 22(26): 6027-6035 [PMID: 27468194 DOI: 10.3748/wjg.v22.i26.6027] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
47 Rieder F. Toward an antifibrotic therapy for inflammatory bowel disease. United European Gastroenterol J 2016;4:493-5. [PMID: 27536358 DOI: 10.1177/2050640616660000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
48 Griffey RT, Fowler KJ, Theilen A, Gutierrez A. Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. Ann Emerg Med 2017;69:587-99. [PMID: 27317304 DOI: 10.1016/j.annemergmed.2016.04.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 De Felice KM, Katzka DA, Raffals LE. Crohn's Disease of the Esophagus: Clinical Features and Treatment Outcomes in the Biologic Era. Inflamm Bowel Dis. 2015;21:2106-2113. [PMID: 26083616 DOI: 10.1097/mib.0000000000000469] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
50 Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9:156-163. [PMID: 25518058 DOI: 10.1093/ecco-jcc/jju016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
51 Desai D. Disease Behaviour in Patients with Crohn’s Disease: A Review. GHOA 2015;3. [DOI: 10.15406/ghoa.2015.03.00076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
52 Moreau J, Mas E. Drug resistance in inflammatory bowel diseases. Curr Opin Pharmacol. 2015;25:56-61. [PMID: 26645664 DOI: 10.1016/j.coph.2015.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
53 González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. J Crohns Colitis 2016;10:55-60. [PMID: 26520164 DOI: 10.1093/ecco-jcc/jjv187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
54 Targownik LE, Suissa S. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research. Am J Gastroenterol 2015;110:1647-50. [PMID: 26323186 DOI: 10.1038/ajg.2015.210] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
55 Chhaya V, Pollok RCG, Cecil E, Subramanian V, Curcin V, Majeed A, Saxena S. Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study. Aliment Pharmacol Ther 2015;42:990-9. [DOI: 10.1111/apt.13361] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
56 Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G. Response to Irwin et al. Am J Gastroenterol 2015;110:933-5. [PMID: 26052772 DOI: 10.1038/ajg.2015.134] [Reference Citation Analysis]
57 Irwin J, Radford-Smith G. Response to Magro et al. Am J Gastroenterol 2015;110:931-2. [PMID: 26052771 DOI: 10.1038/ajg.2015.131] [Reference Citation Analysis]
58 Palmela C, Torres J, Cravo M. New Trends in Inflammatory Bowel Disease. GE Port J Gastroenterol 2015;22:103-11. [PMID: 28868386 DOI: 10.1016/j.jpge.2015.03.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
59 Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G. Response to Targownik. Am J Gastroenterol 2015;110:349-51. [PMID: 25646916 DOI: 10.1038/ajg.2014.376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
60 Targownik L. The importance of accounting for immortal time bias in pharmacoepidemiologic analyses. Am J Gastroenterol 2015;110:349. [PMID: 25646915 DOI: 10.1038/ajg.2014.372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
61 Shimshoni E, Yablecovitch D, Baram L, Dotan I, Sagi I. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut 2015;64:367-72. [PMID: 25416065 DOI: 10.1136/gutjnl-2014-308048] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
62 Pellino G, Sciaudone G, Selvaggi F, Riegler G. Delayed diagnosis is influenced by the clinical pattern of Crohn’s disease and affects treatment outcomes and quality of life in the long term: a cross-sectional study of 361 patients in Southern Italy. European Journal of Gastroenterology & Hepatology 2015;27:175-81. [DOI: 10.1097/meg.0000000000000244] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 4.9] [Reference Citation Analysis]